On Statistical Approaches for Demonstrating Analytical Similarity in the Presence of Correlation

Reference

1. 1.↵
   FDA Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: U.S. FDA: Silver Spring, MD, 2015.
2. 2.↵
   1. Chow S.-C.

   Challenging Issues in Assessing Analytical Similarity in Biosimilar Studies. Biosimilars 2015, 5, 33–39.

   OpenUrl
3. 3.↵
   FDA Guidance for Industry: Quality Considerations in Demonstrating Biosimiarity to a Reference Protein. U.S. FDA: Silver Spring, MD, 2015.
4. 4.↵
   FDA Guidance for Industry: Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009. U.S. FDA: Silver Spring, MD, 2015.
5. 5.↵
   FDA (2006). “Guidance for Industry: ICH Q9 Quality Risk System”. Silver Spring, MD: The United States Food and Drug Administration.
6. 6.↵
   1. Chow S.-C.

   On Assessment of Analytical Similarity in Biosimilar Studies. Drug Designing: Open Access 2014, 3, 119; doi:10.4172/2169-0138.1000e124.

   OpenUrlCrossRef
7. 7.↵
   U.S. FDA. FDA Briefing Document for the Oncologic Drugs Advisory Committee (ODAC) Meeting, January 7, 2015 (http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM428781.pdf).
8. 8.↵
   1. Dong X.,
   2. Shen M.,
   3. Tsong Y.

   EP2006 Statistical Equivalence Testing for Bioactivity and Content 2015; http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM431118.pdf.
9. 9.↵
   1. Dong X.

   Equivalence test for biosimilar analytical assessment. Second Statistical and Data Management Approaches for Biotechnology Drug Development, USP Headquarters, Rockville, MD, 2015.
10. 10.↵
    1. Shen M.,
    2. Dong X.,
    3. Tsong Y.

    Equivalence Margin Determination for Analytical Biosimilar Assessment, 2015 FDA Industry Statistics Workshop, Washington, DC, September 16–18, 2015.
11. 11.↵
    1. Tsong Y.,
    2. Shen M.,
    3. Dong X.

    Development of Statistical Approaches for Analytical Biosimilarity Evaluation, 2015 DIA/FDA Statistical Forum, Rockville, MD, April 2015.
12. 12.↵
    1. Tsong Y.

    Statistical Strategies for Determining Biosimilarities, 2015 Nonclinical Biostatistics Conference, Villanova, PA, October 13–15, 2015.
13. 13.↵
    1. Berger R.,
    2. Hsu J.

    Bioequivalence Trials, Intersection-union Tests and Equivalence Confidence Sets. Statist. Sci. 1996, 11 (4), 283–319.

    OpenUrlCrossRef
14. 14.↵
    1. Satterthwaite F. E.

    An Approximate Distribution of Estimates of Variance Components. Biometrics Bulletin 1946, 2, 110–114.

    OpenUrlCrossRefPubMedWeb of Science
15. 15.↵
    1. Chow S. C.,
    2. Liu J. P.

    Design and Analysis of Bioavailability and Bioequivalence Studies, 3rd ed.; Chapman & Hall/CRC Press: Boca Raton, FL, 2008.
16. 16.↵
    1. Burdick R. K.

    Comments on Analytical Similarity Session, FDA-Industry Statistics Workshop, Washington DC, September, 2015.
17. 17.↵
    1. Liao J. J. Z.,
    2. Darken P. F.

    Comparability of Critical Quality Attributes for Establishing Biosimilarity. Statistics in Medicine 2013, 32 (3), 462–469.

    OpenUrl
18. 18.↵
    1. Weese D.,
    2. Burdick R. K.

    Statistical Details of Analytical Similarity for Biosimilars: An Industry View, IABS/FDA Statistical and Data Management Approaches for Biotechnology Drug Development, Rockville, MD, September, 2015.
19. 19.↵
    1. Tsui K.,
    2. Weerahandi S.

    Generalized p-values in Significance Testing of Hypotheses in the Presence of Nuisance Parameters. Journal of the American Statistical Association 1989, 84 (406), 602–607.

    OpenUrlCrossRefWeb of Science
20. 20.↵
    1. Weerahandi S.

    Generalized Confidence Intervals. Journal of the American Statistical Association 1993, 88 (410), 899–905.

    OpenUrlCrossRefWeb of Science
21. 21.↵
    1. Hannig J.,
    2. Iyer H.,
    3. Patterson P.

    Fiducial Generalized Confidence Intervals. Journal of the American Statistical Association 2006, 101 (473), 254–269.

    OpenUrlCrossRefWeb of Science
22. 22.↵
    1. Burdick R. K.,
    2. Borror C. M.,
    3. Montgomery D.

    Design and Analysis of Gauge R&R Studies: Making Decisions with Confidence Intervals in Random and Mixed ANOVA Models; ASA-SIAM Series on Statistics and Applied Probability: Philadelphia, PA, 2005.
23. 23.↵
    1. Kelley K.

    Confidence Intervals for Standardized Effect Sizes: Theory, Application, and Implementation. Journal of Statistical Software 2007, 20 (8), 1–22.

    OpenUrl
24. 24.↵
    1. Burdick R. K.,
    2. Ramírez J. G.

    Statistical Issues in Biosimilar Analytical Assessment: Perspectives on FDA ODAC Analysis, DIA/FDA Statistics 2015 Forum, Washington, DC, April, 2015.
25. 25.↵
    1. Lostritto R.

    Advisory Committee for Pharmaceutical Science Meeting (in transcripts), October 2005, Vol. 25; p 361. http://www.fda.gov/ohrms/dockets/ac/05/transcripts/2005-4187T1.pdf. Accessed September 11, 2008.
26. 26.↵
    1. Novick S.,
    2. Christopher D.,
    3. Dey M.,
    4. Lyapustina S.,
    5. Golden M.,
    6. Leiner S.,
    7. Wyka B.,
    8. Delzeit H. J,
    9. Novak C.,
    10. Larner G.

    A Two One-sided Parametric Tolerance Interval Test for Control of Delivered Dose Uniformity. Part 1—Characterization of FDA Proposed Test. AAPS PharmSciTech 2009, 10 (3), 820–828.

    OpenUrlPubMed
27. 27.
    1. Apostol I.,
    2. Brooks P. D.,
    3. Mathews A. J.

    Application of High-precision Isotope Ratio Monitoring Mass Spectrometry To Identify the Biosynthetic Origins of Proteins. Protein Sci. 2001, 10 (7), 1466–1469.

    OpenUrlPubMed